Login to Your Account

Asklepios adds Actus, explores AAV gene therapy in Pompe disease

By Marie Powers
News Editor

Friday, December 15, 2017

Asklepios Biopharmaceutical Inc. (Askbio) formed Actus Therapeutics Inc., another in its string of so-called spinout special purpose entities, or SPEs, to pursue therapies for rare genetic diseases, beginning with Pompe disease.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription